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Abstract
A major challenge for strategies to combat the human malaria parasite Plasmodium vivax is the presence of hypnozoites in
the liver. These dormant forms can cause renewed clinical disease after reactivation through unknown mechanisms. The
closely related non-human primate malaria P. cynomolgi is a frequently used model for studying hypnozoite-induced
relapses. Here we report the generation of the first transgenic P. cynomolgi parasites that stably express fluorescent markers
in liver stages by transfection with novel DNA-constructs containing a P. cynomolgi centromere. Analysis of fluorescent liver
stages in culture identified, in addition to developing liver-schizonts, uninucleate persisting parasites that were atovaquone
resistant but primaquine sensitive, features associated with hypnozoites. We demonstrate that these hypnozoite-forms
could be isolated by fluorescence-activated cell sorting. The fluorescently-tagged parasites in combination with FACS-
purification open new avenues for a wide range of studies for analysing hypnozoite biology and reactivation.
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Introduction
Plasmodium vivax is the most widely distributed cause of human
malaria having an enormous socio-economical impact with an
estimated 132 to 391 million clinical cases per year [1]. There is an
increased awareness of the severity of the disease that P. vivax can
cause [2,3], yet radical cure of P. vivax infections is hampered by
the existence of hypnozoites, which are dormant forms present in
the liver that can cause blood stage infections upon reactivation
[4]. Hypnozoites are insensitive to most anti-malarial drugs that
kill developing blood- and liver stages [5]. Primaquine is currently
the only available drug that kills the dormant hypnozoites, but its
severe side effects in glucose-6-phosphate dehydrogenase (G6PD)-
deficient people prevent the widespread use of the drug [6]. The
presence of hypnozoites and their drug-insensitivity form a major
hurdle for elimination programmes and it is generally agreed that
the mission to eradicate malaria initiated by Bill and Melinda
Gates [7] can only be successful if effective means exist to remove
this hidden reservoir of hypnozoites from the population [5,8].
Despite the importance of hypnozoites for initiating relapse-
infections hardly anything is known about their biology and the
mechanisms underlying dormancy and reactivation of these forms.
This is mainly due to the absence of robust in vitro culture systems
not only for liver stages (including hypnozoites), but also for any
other P. vivax life cycle stage [9]. Recently a small-scale liver
culture system for P. vivax, relying on cryopreserved sporozoites
has been described [10], and small forms expressing CSP were
seen at day 9. However, more work is needed to demonstrate that
these forms are hypnozoites.
Access to P. vivax sporozoites and P. vivax relapse research in vivo
in animal models is severely hampered by its host range that is
restricted to some New World monkey species and chimpanzees
[2,8]. Consequently, much of the knowledge on the biology of
vivax-type parasites is derived from studies using a closely related
non-human primate malaria parasite Plasmodium cynomolgi [11].
This parasite also forms hypnozoites and has been the gold-
standard in vivo model for studying relapse-infections that result
from reactivation of hypnozoites [2]. Recently, technologies have
been developed for the in vitro cultivation of the liver stages of P.
cynomolgi. Similar to what was observed in P. vivax [10], this
included forms that resemble hypnozoites [12].
In vitro cultures of Plasmodium liver stages in which hypnozoite-
forms are produced are exciting developments offering new
possibilities to investigate the biology of hypnozoites and,
importantly, for screening drugs that target these forms. However,
these analyses need to be robust and amenable to high throughput
methodologies, and currently this can only realistically be achieved
through genetic modification of the P. cynomolgi genome, whereby
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it is possible to create transgenic reporter parasites and gene-
deletion mutants as has been shown for other Plasmodium parasites
[13–19]. Thus far transfection technology for P. cynomolgi is not
well developed [20,21] and transgenic parasites expressing
fluorescent markers for analysis of liver stages are not available.
Recently the use of a Plasmodium artificial chromosome (PAC) as
transfection tool has been reported for the rodent malaria P. berghei
[22]. In this study it was shown that transfection with DNA
constructs containing a centromeric sequence results in stable
maintenance and segregation of both circular and linear DNA
constructs throughout the complete life cycle including mosquito
transmission and liver stage development. We have adopted this
technology to generate for the first time P. cynomolgi mutant
parasites that stably express fluorescent reporters in liver stages.
These reporter parasites were generated by transfection using
a novel DNA-construct that contains a P. cynomolgi centromeric
sequence and two reporter proteins, mCherry and GFP under the
control of two different promoters. Analysis of fluorescent liver
stages of these reporter parasites identified developing liver-
schizonts and fluorescent, uninucleate persisting forms that
showed all characteristics of hypnozoite-forms. Importantly, we
were able to sort these hypnozoites-forms by fluorescence-
activated cell sorting (FACS) based on their GFP-fluorescence
intensity. These reporter lines and technologies to isolate
hypnozoite-forms provide new tools not only to analyse hypno-
zoite biology and reactivation but also for larger scale screening of
drugs that target hypnozoites-forms.
Results
Episomal Transfection of P. Cynomolgi using a DNA-
construct Containing a Putative P. cynomolgi Centromere
In the absence of robust and efficient methods to generate
transgenic P. cynomolgi parasites by double crossover integration of
DNA constructs into the genome we aimed for generation of
transgenic parasites using episomal transfection. A disadvantage of
episomal transfection is that transgenic Plasmodium parasites
rapidly loose circular DNA-constructs during propagation in the
absence of drug pressure due to uneven segregation of these
constructs during mitosis [23,24]. However when circular (and
linear) DNA constructs contain Plasmodium centromeric sequences,
they are stably segregated and maintained during propagation
throughout the complete life cycle in the absence of drug selection
pressure [22,25]. With the aim to create stably fluorescent
transgenic P. cynomolgi liver stages we therefore decided to include
a centromeric sequence in our transfection construct. We first
transfected P. knowlesi, a close relative of P. cynomolgi and the only
non-human primate parasite that allows easy transfection and
selection of genetically modified mutants in vitro [26,27], with the
centromere-containing P. berghei L-PAC construct [22]. When
drug pressure was removed from the cultures, the L-PAC
construct was rapidly lost. This indicates that the use of
heterologous centromeric sequences does not result in stable
maintenance of episomal constructs in P. knowlesi, similar to what
has been reported in P. berghei [22]. Based on these observations we
decided to first identify a putative P. cynomolgi centromere for
inclusion in DNA constructs for subsequent P. cynomolgi trans-
fection. Using primers based on a putative centromere from P.
vivax (see Materials and Methods and Table S1), a 2.3 kb product
was amplified from P. cynomolgi genomic DNA and sequenced
(deposited at GenBank; accession number JQ809338). Sequence
analysis showed a 93.8% A/T rich region with a core and
a repetitive region as determined by Dotlet analysis (Figure 1A),
characteristics which are indicative of a centromeric region [22]. A
BLAST2 comparison of the sequence of the putative P. vivax
centromeric region PvCEN (located between the genes
PVX_113710 and PVX_113720) with the amplified, putative P.
cynomolgi centromere, PcyCEN, showed an identity of 80% and
Dotlet analyses revealed that the sequence identity was restricted
to the core region, analogous to what has been described for
rodent malaria centromeres [22] (Figure 1A).
In order to generate fluorescent P. cynomolgi liver stage parasites,
we then generated construct pPcyC-PAC-GFPhsp70-mCherryef1a
that includes the 2.3 kb centromeric region of P. cynomolgi
(Figure 1B), a drug-selectable marker cassette [20] and two
reporter genes gfp and mCherry under the control of ‘constitutive’
promoters. In the absence of genome data for P. cynomolgi we used
the promoter regions of two P. knowlesi genes, hsp70
(PKH_051230) and ef1a (PKH_111400). For both the Plasmodium
hsp70 and ef1a genes evidence has been found for constitutive
expression throughout the life cycle [19,28]. In addition we
selected hsp70 as we had found that anti-HSP70 antibodies stain P.
cynomolgi liver stage cultures, including hypnozoite-forms.
The final construct, pPcyC-PAC-GFPhsp70-mCherryef1a (a
circular artificial chromosome containing a homologous centro-
mere and two marker genes) was used to transfect blood stages
of P. cynomolgi. Because monkeys are necessary for these
experiments, the procedure requires a robust system for
collection and transfection of blood stages. Therefore we first
optimised the enrichment procedure for P. cynomolgi blood stages
(see Materials and Methods) resulting in a protocol (Figure 1C)
that includes purification of infected blood cells by Nycodenz-
density centrifugation [29], yielding a parasite preparation
containing $95% red blood cells (rbc) infected with tropho-
zoites and young schizonts. Subsequently 26107 Nycodenz-
purified, infected rbc were transfected with the pPcyC-PAC-
GFPhsp70-mCherryef1a construct using the Nucleofector technol-
ogy [30] and these parasites were intravenously inoculated into
a recipient monkey directly after transfection. Seven days post
infection, the first parasites were observed and a day later
pyrimethamine treatment was started to select transfected
parasites. At day 13 a blood infection became patent again
and at day 18, at a 2.4% parasitemia, the monkey was bled for
preparing cryo-preserved parasite stocks and ex vivo mosquito
feeding. In addition at day 20 blood was collected for a second
mosquito feeding and for parasite genotyping and phenotyping.
Genotype analysis by amongst others diagnostic PCR analysis
(Figure 1D) showed the presence of the intact pPcyC-PAC-
GFPhsp70-mCherryef1a constructs in the parasites. Moreover,
fluorescence microscopy showed GFP- and mCherry-expression
in blood stages of the PcyC-PAC-GFPhsp70-mCherryef1a para-
sites (Figure 1E). A global analysis of Hoechst-stained blood
stages showed that most, if not all, trophozoites and schizonts
were GFP- and mCherry positive. These results show that
transgenic P. cynomolgi parasites can be selected that are
episomally transfected using constructs containing a centromeric
region. In addition it shows that the hsp70 and ef1a 59UTR
regions of P. knowlesi can drive expression of reporter genes in P.
cynomolgi. These PcyC-PAC-GFPhsp70-mCherryef1a parasites have
been used for analysis of liver stage development (see below).
The same procedure as for generation of PcyC-PAC-GFPhsp70-
mCherryef1a parasites has now been applied in our laboratory in
five independent experiments and in all experiments we
successfully selected transgenic P. cynomolgi parasites (data not
shown), indicating that this procedure as shown in Figure 1C is
a robust system for P. cynomolgi transfection.
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pPcyC-PAC-GFPhsp70-mCherryef1a is stably Maintained in
P. cynomolgi and the P. knowlesi ef1a and hsp70
Promoters are Active Throughout the P. cynomolgi Life
Cycle
To analyse maintenance of the DNA construct in parasites
throughout the life cycle, we infected Anopheles stephensi mosquitoes
with the PcyC-PAC-GFPhsp70-mCherryef1a parasites as described
above. The mean number of oocysts 7 days after feeding in 10
independent experiments showed a wide variation ranging from 2
to .200 oocysts. This variation in oocyst production was also
observed in A. stephensi that had been fed with wild type P.
cynomolgi. Also sporozoite production of PcyC-PAC-GFPhsp70-
mCherryef1a parasites was comparable to that of wild type
parasites (a mean of 54,309 transgenic salivary gland sporo-
zoites/mosquito derived from 10 transmission experiments com-
pared to a mean of 53,125 wild type sporozoites/mosquito derived
from 15 transmissions). Fluorescence microscopy of infected
midguts and salivary glands revealed the presence of brightly
fluorescent oocysts and salivary gland sporozoites, expressing both
GFP and mCherry (Figure 1E). A limited survey indicated that,
similar to centromere constructs in P. berghei [22], the majority of
oocysts and sporozoites were fluorescent. In blood stages, oocysts
and sporozoites, we never observed parasites that did not express
mCherry and GFP simultaneously, indicating the constitutive
nature of the promoters driving expression of the fluorescent
markers. The normal oocyst and sporozoite production by PcyC-
PAC-GFPhsp70-mCherryef1a indicates that expression of the re-
porter proteins does not grossly affect parasite development in the
mosquito.
We next analysed development of PcyC-PAC-GFPhsp70-mCher-
ryef1a parasites during liver stage development using in vitro
cultures of rhesus primary hepatocytes. Fluorescence microscopy
analysis of live parasites at day 6 post infection with sporozoites
shows maturing forms that are characterised by multiple nuclei
(Hoechst staining) and their large size (Figure 1E). In addition,
small uninucleate forms are present at day 6 (Figure 1E, arrow).
Both the multinucleate and uninucleate forms are GFP and
mCherry-positive and both forms stain with anti-HSP70 anti-
bodies after fixation of the cells (Figure 1E). Because of the high
background fluorescence of primary hepatocytes using standard
FITC filter settings, as has also been reported previously [31], GFP
expression in liver stages is sometimes hard to detect. However,
careful analyses using long pass filters (see Materials and Methods)
allowed the discrimination of GFP from background fluorescence
and showed that mCherry-positive multinucleate and uninucleate
forms were also GFP-positive. To determine whether all liver stage
parasites expressed mCherry/GFP, using images taken by the
Operetta High Content Imaging System (PerkinElmer), total
numbers of mCherry/GFP expressing EEF were counted and
compared to the total number of EEF from the same fields as
assessed by HSP70 staining of fixed parasites. Figure 2A shows the
results of the counts, derived from three independent experiments,
counting $5 fields per experiment. Calculating the percentage of
EEF that expressed mCherry/GFP revealed that a mean of 66%
of EEF expressed mCherry/GPF (range 57–73%), indicating that
the majority of parasites retain the construct during mosquito
transmission and liver stage development, comparable to stable
maintenance of centromere-containing constructs in mosquito
transmission and hepatocyte infection of P. berghei [22]. A strong
indicator for the presence of hypnozoites is their resistance to
atovaquone [12]. To determine whether these stages were
expressing mCherry/GFP, we treated liver stage cultures with
100 nM atovaquone to kill all developing parasites. Again, the
total numbers of mCherry/GFP expressing EEF were counted and
compared to the total number of EEF (only small forms in this
case) from the same fields as assessed by HSP70 staining of fixed
parasites. The total small form EEF counts from two independent
experiments (counting 10 fields per experiment) are depicted in
Figure 2A in the right panel. This showed that in the two
experiments 54% and 63% of the atovaquone resistant EEF
expressed GFP/mCherry, similar to the total number of untreated
EEF that express GFP/mCherry. Thus we conclude that both
small and developing EEF can consistently be detected by either
antibody staining or live imaging of GFP/mCherry.
The Operetta system not only provides the opportunity to
analyse fluorescent images taken at different time points but also
allows for automated counting of parasites that are recognized
based on different characteristics of the cells, i.e. their morphology
and their fluorescence intensity. Automated counting HSP70-
stained PcyC-PAC-GFPhsp70-mCherryef1a multinucleate and uni-
nucleate parasites at day 6 post infection showed a mean
percentage of infected liver cells of 0.34% (range 0.24% to
0.48%; 3 exp; 13 wells in total). This infection rate is comparable
to the mean infection rate (0.39%) of wild type parasites that were
present in the same plates (range 0.25% to 0.71%; 11 wells in
total). These experiments also showed that for the transgenic
parasites, the percentage of small stages ranged from 57–65% and
for wild type parasites this was 57–63%. This averaged for both to
a ratio of 39% multinucleate versus 61% uninucleate parasites,
indicating that there was no difference in this ratio due to the
presence of the centromeric construct. The percentage of small
forms in P. cynomolgi liver stage cultures can vary from experiment
to experiment (Zeeman et al., in preparation) and may, amongst
Figure 1. Construction and analysis of fluorescent P. cynomolgi using a novel centromere construct. (A) Dot matrix analysis of a P.
cynomolgi and P. vivax putative centromere (PCEN). Graphical representation of a matrix analysis of a P. cynomolgi PCEN aligned against itself (left), P.
cynomolgi PCEN against the P. vivax PCEN (middle) and P. vivax PCEN aligned against itself (right). The analysis was performed using Dotlet [46] as
described before [22]. The diagonal line within each analysis represents sequence identity, and the diagonal line indicates repetitive regions within
each PCEN. Note the absence of the diagonal in the repetitive regions of the P. cynomolgi and P. vivax alignment (Figure 1, middle panel). (B)
Schematic representation of the pPcyC-PAC-GFPhsp70-mCherryef1a plasmid. The plasmid contains the Tgdhfr-ts selectable marker that confers
resistance against pyrimethamine and two expression cassettes for constitutive expression of GFP and mCherry. Additionally, to maintain the plasmid
throughout the life cycle, a putative P. cynomolgi centromere (PcyCEN) is included. (C) Schematic representation of the procedure used for
transfection and analysis of P. cynomolgi. (D) PCR amplification of gfp and mCherry in PcyC-PAC-GFPhsp70-mCherryef1a (PcyC-PAC) blood stage
parasites. Wild type gDNA of P. cynomolgiM served as negative control. For a control PCR primers for the circumsporozoite protein (csp) were used. For
primers used, see Table S1. (E) GFP and mCherry expression throughout the life cycle of P. cynomolgi. GFP and mCherry expression in pPcyC-PAC-
GFPhsp70-mCherryef1a transfected P. cynomolgi blood stage parasites (a ring and a trophozoite or gametocyte), in oocysts 5 days post mosquito
feeding and in salivary gland sporozoites 12 days post feeding. In the Brightfield panel two salivary gland lobes can be distinguished; only one lobe
contains sporozoites. In the panel on the right GFP and mCherry expression is shown in Hoechst 33342 stained day 6 liver stages. Note the
autofluorescence of hepatocytes in the GFP channel in contrast to the mCherry channel. A small uninucleate (arrow) and a large multinucleate liver
stage are visible, confirmed by staining of fixed parasites with anti-HSP70 antibodies (lower right panel). White bars correspond to 10 mm (blood and
mosquito stages) and 50 mm (liver stages).
doi:10.1371/journal.pone.0054888.g001
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Figure 2. Identification and characterisation of P. cynomolgi hypnozoite-forms. (A) Exo-erythrocytic forms (EEF) counted live (GFP and
mCherry positive) and fixed (after HSP70 staining), 6 days post hepatocyte infection. Total EEF numbers were counted in ‘untreated’ wells containing
complete medium (three experiments, at least five fields counted per experiment) or wells that contained medium with 100 nM atovaquone
throughout (two experiments, ten fields counted per experiment). (B) Real time monitoring of development of P. cynomolgi liver stages. Overlay of
mCherry and GFP pictures taken at regular time intervals of P. cynomolgi liver stages. The left panel shows growth of a P. cynomolgi liver schizont
towards its development into a multinucleate schizont. The right panel shows the presence of a small persistent liver stage parasite over a period of
11 days. Fixation and staining with anti-HSP70 antibodies and DAPI confirmed the presence of a multinucleate liver schizont and a small uninucleate
parasite. The white bar corresponds to 50 mm. (C) Percentages of P. cynomolgi EEFs relative to EEF in untreated control wells post drug. P. cynomolgi
wild type and PcyC-PAC-GFPhsp70-mCherryef1a (PcyC-PAC) liver stage cultures were harvested at day six post hepatocyte infection following
Transgenic Fluorescent Malaria Hypnozoite-Forms
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others, depend on the quality of the batch of primary hepatocytes
used.
These results indicate that i) expression of the reporter proteins
does not affect invasion of liver cells and further development of
the transgenic parasites, ii) stable maintenance of the centromeric
construct enables the production of high percentages of fluorescent
P. cynomolgi liver stage parasites, and iii) the heterologous
promoters are active throughout the life cycle.
Analysis of Developing P. cynomolgi Liver Stages and
Hypnozoite-forms by Live Imaging
As described above we observed both multinucleate and small
uninucleate parasites at day 6 after infection of the primary rhesus
hepatocytes with PcyC-PAC-GFPhsp70-mCherryef1a sporozoites,
indicating that a percentage of parasites arrest development. To
analyse the development of these different forms we evaluated liver
stages by live imaging throughout their development in culture. At
day 2 only small parasite forms are present that are hardly visible/
detectable by fluorescence microscopy. Between days 2 and 3
these small forms increase in size. After day 3 we distinguish two
different forms in the cultures; forms that do not further increase in
size and which remain uninucleate (Figure 2B, right column) and
forms that increase in size and start nuclear division (at day 3 to 4),
which progress to large multinucleate schizonts at day 11
(Figure 2B, left column). These large parasites appear with large
vacuoles similar to what has been described for mature P. yoelii
liver stage schizonts [13]. The persisting, small and uninucleate
forms resemble the hypnozoite-forms described previously [12].
The Hypnozoite-forms are Resistant to Atovaquone but
are Killed by Primaquine
A characteristic of hypnozoites is their resistance to atovaquone
treatment while they are killed by primaquine [12]. To further
investigate the nature of the small fluorescent forms in our
cultures, we treated cultures of wild type and PcyC-PAC-
GFPhsp70-mCherryef1a with atovaquone and primaquine at
concentrations that kill developing P. cynomolgi liver stage parasites
[12]. Treatment was started three hours after adding the
sporozoites to the primary rhesus hepatocytes and at day 6 after
sporozoite infection, PcyC-PAC-GFPhsp70-mCherryef1a and wild
type parasites were counted using the Operetta. Automated
counting of fixed cells (based on their morphology and anti-HSP70
antibody staining) showed that, as expected, both PcyC-PAC-
GFPhsp70-mCherryef1a and wild type developing liver stages were
killed by the concentrations of atovaquone and primaquine used
(Figure 2C). Small forms of both transgenic and wild type parasites
were killed by primaquine, while a significant population of small
forms was still present after atovaquone treatment (Figure 2C).
These data show that there was no difference in drug activities
against the transgenic liver stage parasites compared to the wild
type parasites and suggest the presence of hypnozoite-forms in
these cultures, analogous to what has been reported before [12].
For automated counting of live cells we developed a custom-
adapted Harmony script based on mCherry and GFP fluorescence
intensity and morphology (Perkin Elmer, see Materials and
Methods). Counting of live PcyC-PAC-GFPhsp70-mCherryef1a cells
showed comparable results to the counting of fixed parasites
(Figure 2C). Treatment with primaquine resulted in the disap-
pearance from the cultures of not only the large, developing stages
but also of the small persistent forms. In contrast, these fluorescent
small, persistent forms remained present in the cultures that were
treated with atovaquone (Figure 2C). This was confirmed by
a manual comparison of the live and fixed images obtained from
atovaquone treated cultures (Figure 2A). The insensitivity to
atovaquone and their killing by primaquine strongly supports the
conclusion that these small, fluorescent parasites that persist for
prolonged periods in culture, are hypnozoite-forms. In addition
these results demonstrate that the transgenic parasites can be used
in drug assays with live imaging read out.
Hypnozoite-forms can be Isolated by Flow Sorting
The small size and low numbers of the hypnozoite-forms in
culture, in addition to their intracellular location in a large host
cell, hampers detailed analysis of the biology of these hypnozoite-
forms, for example it excludes RNAseq or proteome analyses of
these stages. We therefore investigated whether it was possible to
purify these stages by flow sorting based on their fluorescence
characteristics. We first analysed GFP-fluorescence intensity by
flow cytometry of infected primary rhesus hepatocytes at day 3 and
day 6 after infection of the cultures with PcyC-PAC-GFPhsp70-
mCherryef1a sporozoites. At day 3 a clear population could be
distinguished that showed an increased GFP-fluorescence intensity
(cells in Gate 1 in Figure 3A) compared to uninfected hepatocytes.
This population represents hepatocytes infected with GFP-positive
parasites, as this population is absent in parallel cultures of wild
type liver stages (Figure 3A). At day 6 infected cells were observed
with the same GFP-fluorescence intensity as on day 3 (cells in Gate
2 in Figure 3B) and cells with increased GFP intensity (cells in
Gate 3 in Figure 3B). The percentage of infected cells with low
GFP intensity (Gate 2) of the total infected cells (Gate 2 and 3) was
57% (range 47% to 63%; 3 exp.) and is in line with data from
manual (fluorescence microscopy) and automated counting
(Operetta System) of hypnozoite- and developing-forms, as also
reported above. To further investigate the two different popula-
tions, cells were flow sorted from Gate 2 and Gate 3 as shown in
Figure 3B and these cells were imaged using the Operetta system.
Cells sorted from Gate 2 (three independent experiments) were
GFP and mCherry-positive parasites of which on average 97%
(range 90% to 100%; 3 exp.) were small uninucleate parasite
stages (hypnozoite-forms), whereas cells from Gate 3 were mainly
developing liver stage parasites (35%–83%; 3 exp.; Figure 3C).
These results demonstrate that it is possible to purify a population
of small, uninucleate parasites that includes hypnozoite-forms.
Most sorted parasites, both the small forms and developing forms,
were extracellular. This may be due to the small nozzle size used
during the sorting procedure, and/or to increased hepatocyte
fragility resulting from collagenase treatment. Preliminary data
suggest that trypsinization of the cells instead of collagenase
treatment appears to improve the integrity of the cells and
overcome the problems associated with host cell rupture.
continuous treatment with 100 nM atovaquone or 10 mM primaquine. Small uninucleate and developing (‘large’) parasites were counted on a high-
content imaging system (PerkinElmer) according to custom made algorithms for live or fixed liver stage parasites using Harmony software (see
Materials and Methods). Parasite counts were compared to EEF counts from untreated control wells and shown as percentages. Percentages of
atovaquone and primaquine treated parasites are depicted superimposed. Live measurements of untreated PcyC-PAC control wells showed total
numbers of EEF per well ranging from 16–377 (average number 132). For fixed measurements of PcyC-PAC, untreated control wells contained total
EEF numbers ranging from 26–377 (average number 258) and for fixed WT measurements, control wells contained total EEF numbers ranging from
58–382 (average number 212). The results of three independent P. cynomolgi in vitro liver stage assays are represented as mean with SD.
doi:10.1371/journal.pone.0054888.g002
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Following this method, we estimate to obtain some 5,000 sort
events for small as well as developing forms from an optimal large-
scale experiment. Combining purified material from several
experiments, each requiring the infection of a rhesus monkey
with the transgenic parasite, should yield sufficient material for
subsequent –omic analyses, similar to described by Tarun et al.,
who used some 40,000 purified rodent malaria EEF for such
analyses [36].
Discussion
At present extremely little is known about hypnozoites, the
dormant malaria liver stages, mainly due to the technical hurdles
associated with working with P. vivax and the lack of tools to study
the biology of this cryptic parasite stage [2,8]. Here, we report the
development of novel tools to dissect hypnozoite biology using P.
cynomolgi as a hypnozoite-forming model malaria parasite. An
advantage of working with this species is the readily and
reproducible access to sporozoites, which is required for studies
on liver stages using in vitro cultivation technologies. Episomal
transfection of P. cynomolgi has already been reported for P.
cynomolgi [20], but we have now developed a novel DNA-construct
containing a centromeric region in order to maintain episomes
throughout the life cycle and to express fluorescent-proteins in the
liver stages. This is the first time that a centromere-containing
construct is used in a non-rodent malaria parasite to express
(reporter) proteins in liver stages. Not all liver stage parasites could
be visualized, indicating that in the absence of drug selection in the
mosquito, some of the constructs may have been lost. This could
be overcome by integrating the marker genes into the genome
using gene insertion. Although published by others [21], this
technology has not yet been fully established in our laboratories.
Nonetheless, the presence of the centromere enabled expression of
marker genes in a significant proportion of the liver stage parasites,
including hypnozoite-forms. This shows that episomally main-
tained centromere-containing constructs provide a new, simple
approach for (over-) expression of proteins in many developmental
stages, including the liver stages. Moreover, next to stable
maintenance, in the rodent parasite P. berghei [22] and the human
parasite P. falciparum [25] it has been shown that transfection with
centromere-containing constructs (linear or circular) is highly
efficient. Given the current limitations for in vitro cultivation of P.
vivax blood stages and transfection of P. vivax [32], it might be
worthwhile to explore whether this approach can be applied for
this species as well.
Development of the PcyC-PAC-GFPhsp70-mCherryef1a parasites
appeared to progress normally throughout the in vivo life cycle,
both in primates and mosquitoes, indicating no significant loss of
fitness of the transgenic parasites due to expression of the two
reporter-proteins and/or the presence of the centromere-contain-
ing construct. Previously it has been shown that P. berghei parasite
development in the mosquito can be affected when two reporters,
GFP and mCherry, were expressed under the control of the same
constitutive promoter, ef1a [15]. The majority of these transgenic
parasites arrested during the oocyst stage. We have not observed
these problems with our construct that contains the 59UTRs of P.
knowlesi hsp70 and ef1a to drive expression of GFP and mCherry,
respectively, indicating that a combination of these two constitu-
tive promoters for driving transgene expression is feasible
throughout the life cycle.
Hsp70-driven expression of GFP was readily observed through-
out the life cycle. Interestingly also salivary gland sporozoites were
clearly GFP-positive. Although HSP70.1 has been detected in
sporozoites before [28], its abundance is very low and also IFA
analysis of P. cynomolgi sporozoites using anti-HSP70 antibodies
provided evidence for low expression compared to liver stages.
GFP expression in the PcyC-PAC-GFPhsp70-mCherryef1a spor-
ozoites is in line with observations on transgenic P. berghei parasites
that also showed hsp70 promoter-driven GFP expression in
sporozoites [33]. It is possible that the GFP seen in sporozoites
is not a result of hsp70 promoter activity in sporozoites but of
carry-over of GFP from oocysts or midgut sporozoites, since GFP
has been reported to have a relatively long half-life [34].
Alternatively, regulatory signals of the endogenous hsp70 gene
that control its expression in sporozoites may be absent in the
transfection construct used leading to ‘aberrant’ expression of GFP
in sporozoites.
The use of PcyC-PAC-GFPhsp70-mCherryef1a parasites pro-
vided the opportunity for a detailed analysis of P. cynomolgi
development in hepatocytes. Hypnozoites of P. vivax type parasites
are described as small uninucleate, persisting liver stage parasites
that are not killed by most antimalarials but are sensitive to
primaquine (and other 8-aminoquinolines) [35]. In hepatocyte
cultures containing PcyC-PAC-GFPhsp70-mCherryef1a parasites we
show the presence of small fluorescent parasite forms that were
uninucleate and persistent, characteristics reminiscent of hypno-
zoites. Primaquine treatment resulted in the disappearance of
these forms whereas in cultures treated with atovaquone, a drug
that kills all pre-erythrocytic stages except hypnozoites [12],
a significant population of small parasites remained alive. This
indicates that these forms are indeed atovaquone-resistant
hypnozoite-forms. Rapid deterioration of the primary hepatocyte
cultures beyond two weeks prohibit witnessing reactivation of these
hypnozoite-forms, if that would be possible at all in vitro, in the
absence of possibly critical physiological factors from the host.
Thus, in the absence of further markers for hypnozoites other than
being small, persistent, uninucleate EEF resistant to atovaquone
and capable of reactivation (the last of which we have not
demonstrated), we prefer the term ‘hypnozoite-form’, to indicate
that these in vitro cultured parasites contain most known
characteristics of hypnozoites. The small number of small forms
that were killed by atovaquone may represent a population of
parasites that abort development for other reasons, similar to non-
dividing pre-erythrocytic stages that are observed in cultures of P.
falciparum liver stages [12].
The robust P. cynomolgi transmission platform and in vitro liver
stage culture capability [12] (A.M. Zeeman, in preparation) provide
important new tools for in vitro drug screening and bring studies
Figure 3. Flow cytometry and cell sorting of P. cynomolgi liver stage parasites, including hypnozoite-forms. (A) Liver stage parasites
used for flowcytometry as detected by anti-HSP70 antibodies 3 days and (B) 6 days post hepatocyte infection. White bars correspond to 50 mm. Note
that day 3 cultures contain uniform small parasites while day 6 cultures contain both small and large liver stages (arrows). Flow cytometric plots of
PcyC-PAC-GFPhsp70-mCherryef1a (PcyC-PAC) P. cynomolgi liver stage parasites show a single GFP positive population compared to wild type parasites
3 days post hepatocyte infection (A, Gate 1) and two GFP positive populations 6 days post hepatocyte infection (B, Gates 2 and 3). The y-axis
represents the PE-Texas Red Channel (for detection of autofluorescence), while the x-axis represents the GFP signal. (C) Post-sorting images of PcyC-
PAC-GFPhsp70-mCherryef1a P. cynomolgi liver stage parasites ‘GFPlow’ (Gate 2) and ‘GFPhigh’ (Gate 3) parasites sorted at day 6 post hepatocyte
infection. The upper panel shows a GFP/Brightfield overlay while the lower panel shows mCherry/Brightfield overlay. The panels below show close-
ups of the sorted parasites revealing the size differences between the ‘GFPlow’ and ‘GFPhigh’ populations. White bars correspond to 50 mm.
doi:10.1371/journal.pone.0054888.g003
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aiming to investigate hypnozoite biology within reach. However,
hepatocyte infection grades are maximally a few percent meaning
that hypnozoite transcriptomics and proteomics will suffer from
serious amounts of hepatocyte contamination. For the rodent
malaria P. yoelii, FACS purification and subsequent transcriptome
and proteome survey of liver stages using GFP expressing parasites
has been described [13,36]. Importantly here we demonstrate that
a similar approach for P. cynomolgi is feasible. Beyond what has
been achieved with P. yoelii that only produces developing liver
stages, we have shown that we can isolate both developing liver
stages and critically also hypnozoite-forms from infected hepato-
cyte cultures to great levels of purity and after scaling up this
procedure, a detailed molecular characterisation of these stages
should become feasible. In the absence of markers for hypnozoites,
we cannot exclude that, next to hypnozoite-forms, a small parasite
population that has aborted its development is purified alongside.
Therefore, in future large-scale FACS purification experiments,
one solution to avoid this may be to exploit an atovaquone
treatment to kill such stages, as previously described [12].
Given the lack of knowledge of hypnozoites these novel tools for
stable transfection of P. cynomolgi, visualisation of live liver stages
and purification of hypnozoite-forms will most likely provide
a wealth of information on these so far elusive parasite forms,




All rhesus macaques (Macaca mulatta) used in this study were
captive bred for research purposes and were socially housed at the
BPRC facilities under compliance with the Dutch law on animal
experiments, European directive 86/609/EEC and with the
‘Standard for humane care and use of Laboratory Animals by
Foreign institutions’ identification number A5539-01, provided by
the Department of Health and Human Services of the USA
National Institutes of Health (NIH). Nonhuman primates were
used because no other models (in vitro or in vivo) were suitable for
the aims of this project. Besides their standard feeding regime,
animals followed an environmental enrichment program in which,
next to permanent and rotating non-food enrichment, daily an
item of food-enrichment was offered to the macaques. All animals
were daily monitored for health and discomfort. The local
independent ethical committee constituted conform Dutch law
(BPRC Dier Experimenten Commissie, DEC), approved all
research protocols prior to the start and all experiments were
performed according to Dutch and European laws. The Council
of the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC International) has awarded BPRC full
accreditation. Thus, BPRC is fully compliant with the interna-
tional demands on animal studies and welfare as set forth by the
European Convention for the Protection of Vertebrate Animals
used for Experimental and other Scientific Purposes, Council of
Europe (ETS 123), Dutch implementing legislation and the Guide
for Care and Use of Laboratory Animals. The liver lobes were
collected from monkeys that were euthanized in the course of
unrelated studies (ethically approved by the BPRC DEC) or
euthanized for medical reasons, as assessed by a veterinarian.
Therefore, none of the animals from which liver lobes were
derived were specifically used for this work, fully in accordance
with the 3R’s, reducing the numbers of animals used. Euthanasia
was performed under ketamine sedation (10 mg/kg) and was
induced by intracardiac injection of euthasol 20%, containing
pentobarbital. All intravenous injections and large blood collec-
tions were performed under ketamine sedation, and all efforts were
made to minimize suffering.
DNA Constructs
Based on synteny [37], primers were designed against P. vivax
sequence containing a predicted centromere (sequence between
PVX_113710 and PVX_113720). Upon PCR amplification of P.
cynomolgi M strain genomic DNA with a lowered extension
temperature as described earlier [38] using primers 2005 and
2006 (see Table S1 for a list of primers), a fragment of 2.3 kb
containing a putative P. cynomolgi centromere was amplified. The
fragment was cloned into pCRH-Blunt II-TOPO (Invitrogen) and
sequenced. The sequence is deposited to Genbank under accession
number JQ809338. Through a series of cloning steps 0.7 kb of the
39UTR of P. yoelli chloroquine resistance transporter (crt) [39] (kindly
provided by Dr. D. Fidock, GFPmutant3 [40] and 0.7 kb of the 39
UTR of P. knowlesi heat shock protein 70 (hsp70) were cloned into
plasmid pD.DTm.D. [41]. Using the GatewayH Vector Conversion
System (Invitrogen) the plasmid was converted into a destination
vector. Subsequently, P. berghei telomeric regions derived from
plasmid C-PAC [22] were introduced. 1.5 kb of 59UTR of P.
knowlesi hsp70 and 1.1 kb of 59UTR of P. knowlesi elongation factor1a
(ef1a) fused to mCherry were PCR amplified and introduced into
plasmid pDONR221 P1-P5r and pDONR221 P5-P2 using the
MultiSite Gateway Pro Plus system (Invitrogen) to generate entry
clones pENTR 59Pkhsp70L1-L5r and pENTR PkEF-mCherry
L5-L2. These fragments were then simultaneously shuttled into
the destination vector. Finally, the putative P. cynomolgi centromere
was cloned in between the telomeric regions to generate plasmid
pPcyC-PAC-GFPhsp70-mCherryef1a (Figure 1B). Primers used for
amplifying the various parts of the construct are depicted in table
S1. PCR products were sequenced for confirmation.
Parasite Manipulations
To optimise the enrichment procedure for P. cynomolgi blood
stage parasites, we collected P. cynomolgi infected blood at the
BPRC from monkeys from unrelated experiments that had been
ethically approved by the BPRC DEC, and tested it on 52, 55, 58
and 60% Nycodenz cushions (similar to what has been done in P.
yoelii [42]). In three independent experiments this consistently
yielded the highest purity levels of trophozoite/young schizont
preparations at 55% Nycodenz and therefore this was chosen for
enrichment of parasites for transfection. A P. cynomolgi M strain
infection was initiated in a rhesus monkey (Macaca mulatta) by
intravenous injection of 16106 blood stage parasites from
a cryopreserved stock. At peak parasitemia (as monitored by
reading Giemsa-stained thin blood films prepared from finger
prick derived blood) heparin blood was taken and parasites,
mainly young trophozoites, were purified on a 55% Nycodenz
(Axis-Shield) cushion in PBS. After centrifugation at 300 g for
25 min at Room Temperature (low brake), a layer containing
trophozoites at a purity of .95% was isolated and washed in
RPMI 1640. Parasites were cultured overnight in complete
medium (RPMI1640 containing 20% heat inactivated Human
A+ serum and 15 mg/ml gentamicin) for further development and
washed once in RPMI 1640. Subsequently 26107 P. cynomolgi
parasites were resuspended in Human T-cell buffer, mixed with
10 mg of pPcyC-PAC-GFPhsp70-mCherryef1a and transfected using
the Nucleofector device (Lonza, program U33). Immediately after
the pulse, PBS was added to a total volume of 0.5 ml that was
injected intravenously into a recipient monkey. One week later the
monkey was positive for blood stage parasites and pyrimethamine
treatment was initiated (1 mg/kg, orally on a biscuit every other
day) to select for transfected parasites. Six days later a resistant
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parasite population emerged and at peak parasitemia blood was
obtained for stocks, mosquito feeding and analyses. Mosquito
feedings were performed on blood obtained from the recipient
monkey from the transfection or, for further transmission
experiments, donor monkeys were infected with thawed stocks of
PcyC-PAC-GFPhsp70-mCherryef1a blood stage parasites and from
day 2 onwards treated every other day with pyrimethamine until
day 8. Patency usually occurs at day 7 and at parasitemias ranging
from 0.2% to 1.7% (generally between days 11 and 14) mosquitoes
were allowed to feed on two different days on blood obtained from
the monkey.
Mosquito Stages of P. cynomolgi
Two to five days old female Anopheles stephensi mosquitoes Sind-
Kasur strain Nijmegen (Nijmegen UMC St. Radboud, De-
partment of Medical Microbiology [43]) were fed on blood
obtained from a monkey that had been infected with wild type or
PcyC-PAC-GFPhsp70-mCherryef1a parasites using a glass feeder
system. Mosquitoes were housed in climate chambers at 25uC and
80% humidity and fed regularly via cotton soaked in 5% D-
glucose solution. Approximately one week after infection oocysts
were counted and mosquitoes were given an uninfected blood
meal to promote sporozoite invasion of the salivary glands.
Salivary gland sporozoites were present from day 12 post feeding
onwards. PcyC-PAC-GFPhsp70-mCherryef1a blood stages, oocysts
and salivary gland sporozoites were viewed under a Nikon
Microphot FXA fluorescence microscope using filters 485DF22/
505DRLP/515EFLP for GFP expression and 560DF40/
595DRLP/600EFLP for viewing mCherry and pictures were
taken using a Nikon DS-5M digital camera.
Primary Hepatocytes
Rhesus primary hepatocytes were isolated using a two-step
enzymatic perfusion essentially as described [44] and resuspended
in William’s B medium: William’s E with glutamax containing
10% fetal calf serum (FCS), 1% NEAA, 2% penicillin/streptomy-
cin, 1% insulin/transferrin/selenium, 1% NaPyruvate, 50 mM b-
mercapto-ethanol, and 1027 M dexamethasone (Alfasan, Woer-
den, The Netherlands). Hepatocytes were seeded into collagen
coated (5 mg/cm2 rat tail collagen I, Sigma) 96-well Greiner
cellstar plates at a concentration of 96104 cells/well or into 6-well
Costar plates at a concentration of 2.256106 cells/well. Following
attachment, the medium was replaced by William’s B containing
1% dimethylsulfoxide (DMSO) to prevent hepatocyte dedifferen-
tiation.
Sporozoite Inoculation
Between 14 and 28 days post mosquito feeding on P. cynomolgi
infected blood salivary gland sporozoites were isolated and used
for hepatocyte inoculation [45] at a concentration of 56104
sporozoites per well in 96-well plates or at 1.5–26106 sporozoites
per well in 6-well plates. Immediately after sporozoite inoculation
96-well plates were spun at RT at 5006g for 10 min and 6-well
plates were left at room temperature for 2 h to settle the
sporozoites. After placing the plates for two to three hours in
a 37uC incubator at 5% CO2 to allow for sporozoite invasion,
medium was refreshed. From then onwards, medium was
refreshed every other day until the cultures were analysed. For
drug treatment, atovaquone or primaquine were added to the P.
cynomolgi liver stage cultures at the time of the first medium
exchange and added each time medium was refreshed until
fixation in cold methanol at day 6 post sporozoite inoculation.
Visualisation of Exo-erythrocytic Forms (EEF)
Methanol-fixed EEF were stained with antibodies directed
against P. cynomolgi HSP70.1 (A.M. Zeeman, in preparation) as
described [12]. To view nuclei of live parasites, Hoechst 33342
(Invitrogen) was added to the cultures at 10 mg/ml and cultures
were viewed with the Operetta or with the Leica DMI6000
inverted microscope using a Leica I3filter (Excitation filter BP450–
490/Dichromatic Mirror 565/Suppression filter BP600/40) to
visualise GFP and a N3 filter (Excitation filter BP546/12/
Dichromatic Mirror 510/Suppression filter LP 515) to visualise
mCherry in EEF. EEF numbers were determined with a high-
throughput high-content imaging system (Operetta, Perkin-
Elmer).
Custom Scripts for Live and Fixed P. cynomolgi EEF
Using the Harmony software custom scripts for detection of P.
cynomolgi live and fixed EEF were developed empirically. For fixed
parasites, a comparison of more than 100 wells from different
plates showed that numbers and the proportion of small versus
multinucleate forms were similar for manual and automated
counting. For live parasites, comparisons were made between
automated Operetta counts, manually counted EEF and fixed
counted EEF. When necessary, scripts were adjusted to obtain the
best match. For detection of live P. cynomolgi EEF the following
criteria were used: threshold for the mCherry image region was set
at 0.80. Fluorescent populations were counted when the ratio of
mCherry versus autofluorescence was higher than 1.2 in
combination with a mean Hoechst intensity .60 and a mean
GFP intensity .250. Small EEF were characterised by a fluores-
cent image region of .3 mm2 and ,20 mm2. Large EEF had
a fluorescent image region of $20 mm2. For detection of fixed P.
cynomolgi EEF, where staining with antibodies against HSP70 and
subsequent secondary labelling with anti-FITC antibodies had
been performed the criteria for P. cynomolgi EEF were as follows:
the threshold for the Fluorescein image region was 0.83.
Fluorescent populations were counted at a ratio FITC-Autofluor-
escence .5, a DAPI intensity .50 and a Fluorescein intensity
image region .1000. Small EEF were characterised by a fluores-
cent image region of .12 mm2 and ,30 mm2. Large EEF had
a fluorescent image region of $30 mm2.
Flow Cytometric Analyses and EEF Sorting
For FACS, hepatocyte cultures infected with wild type or
pPcyC-PAC-GFPhsp70-mCherryef1a sporozoites were harvested by
Collagenase treatment (Collagenase IV, Sigma, 5 min. at 37uC).
Cells were washed twice in William’s B medium and analysed and
sorted using a BD FACSAria flowcytometer equipped with
a 488 nm CoherentH SapphireTM solid state 20 mW Laser. Data
analyses were performed using FlowJo Version 9.4.10 (TreeStar,
Inc., Ashland OR, USA). The machine was equipped with
a 100 mM nozzle for sorting.
Supporting Information
Table S1 Sequences of oligonucleotides used for con-
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